Effect of continuous sub-culturing on infectivity of Clostridium perfringens ATCC13124 in mouse gas gangrene model
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
28213749
DOI
10.1007/s12223-017-0503-1
PII: 10.1007/s12223-017-0503-1
Knihovny.cz E-zdroje
- MeSH
- bakteriální proteiny genetika metabolismus MeSH
- Clostridium perfringens genetika růst a vývoj fyziologie MeSH
- gangréna plynatá mikrobiologie MeSH
- interakce hostitele a patogenu MeSH
- lidé MeSH
- modely nemocí na zvířatech MeSH
- myši inbrední BALB C MeSH
- myši MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- bakteriální proteiny MeSH
Clostridium perfringens is a Validated Biological Agent and a pathogen of medical, veterinary, and military significance. Gas gangrene is the most destructive of all the clostridial diseases and is caused by C. perfringens type A strains wherein the infection spreads quickly (several inches per hour) with production of gas. Influence of repeated in vitro cultivation on the infectivity of C. perfringens was investigated by comparing the surface proteins of laboratory strain and repository strains of the bacterium using 2DE-MS approach. In order to optimize host-pathogen interaction during experimental gas gangrene infection, we also explored the role of particulate matrix on ability of C. perfringens to cause gas gangrene.
Zobrazit více v PubMed
Res Microbiol. 1996 Jun;147(5):371-84 PubMed
J Clin Microbiol. 1984 Dec;20(6):1099-101 PubMed
J Bacteriol. 2007 Mar;189(5):1514-22 PubMed
J Bacteriol. 2002 Mar;184(5):1430-7 PubMed
Methods Enzymol. 1984;104:237-55 PubMed
Appl Microbiol. 1974 May;27(5):985-7 PubMed
Infect Immun. 2001 Dec;69(12):7904-10 PubMed
Trends Genet. 2003 Aug;19(8):415-7 PubMed
Vaccine. 2003 Mar 7;21(11-12):1187-94 PubMed
Proteomics. 2013 Jan;13(1):89-107 PubMed
Infect Immun. 1999 Sep;67(9):4902-7 PubMed
Anaerobe. 2012 Apr;18(2):254-9 PubMed
Infect Genet Evol. 2015 Aug;34:434-43 PubMed
Infect Immun. 1999 Jan;67(1):131-9 PubMed
Infect Immun. 2010 Sep;78(9):3957-68 PubMed
J Bacteriol. 1996 Dec;178(24):7152-8 PubMed
Infect Immun. 1999 Mar;67(3):1086-92 PubMed
PLoS One. 2011 Jan 31;6(1):e15872 PubMed
J Infect Dis. 1997 Jul;176(1):189-95 PubMed
Anal Chem. 2012 Dec 4;84(23):10500-7 PubMed
Can Med Assoc J. 1941 Aug;45(2):116-8 PubMed
PLoS Pathog. 2006 Jul;2(7):e76 PubMed
FEMS Immunol Med Microbiol. 2008 Jun;53(1):52-9 PubMed
Ann Acad Med Singapore. 1996 Jan;25(1):139-42 PubMed
J Infect Dis. 1987 Feb;155(2):220-8 PubMed
J Proteome Res. 2011 Sep 2;10(9):3880-90 PubMed
J Infect Dis. 1987 Nov;156(5):852-3 PubMed
Bacteriol Rev. 1962 Jun;26:177-276 PubMed
Chin Med J (Engl). 2013 Oct;126(20):3833-9 PubMed
J Clin Microbiol. 1988 Mar;26(3):475-8 PubMed
Infect Immun. 1988 Aug;56(8):1831-6 PubMed
Proteomics. 2006 Jan;6(1):233-50 PubMed
J Bacteriol. 2002 May;184(10):2587-94 PubMed
J Infect Dis. 2004 Aug 15;190(4):767-73 PubMed
Anal Biochem. 1976 May 7;72:248-54 PubMed
BMC Microbiol. 2005 Apr 25;5:19 PubMed
Microbiology. 1997 Jan;143 ( Pt 1):55-61 PubMed
Mol Microbiol. 1999 Nov;34(3):552-61 PubMed
BMC Microbiol. 2009 Aug 10;9:162 PubMed
Trends Microbiol. 1999 Mar;7(3):104-10 PubMed
Infect Immun. 2005 May;73(5):3137-46 PubMed
Mol Gen Genet. 1988 Mar;211(3):435-40 PubMed
